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Background: Dilated cardiomyopathy occurring in HIV-infected patients raises both diagnostic and therapeutic
challenging problems. Indeed myocardial involvement in HIV infection has been variously attributed to several causes,
including viral, toxic, nutritional and autoimmune, but no specific treatment capable to substantially improve patients’
prognosis has been recognized so far.
Case Presentation: Hereby we describe the case of an autoimmune myocarditis manifesting with heart failure in a3
9-year-old man with HIV infection.
Left ventricular endomyocardial biopsy showed a lymphocytic myocarditis characterized by over-expression of HLA-DR
and negative polymerase chain reaction for cardiotropic viruses. Steroid treatment was followed by recovery of cardiac
dimension and function.
Conclusion: Presence of auto-reactive myocarditis should be considered in patients with HIV-associated dilated
cardiomyopathy. Its recognition by endomyocardial biopsy followed by steroid administration may result in a complete
resolution of cardiac disease.
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Occurrence of dilated cardiomyopathy (DCM) in patients
with HIV infection raises particular challenging and investi-
gational problems; indeed it is believed that the intrinsic as
well as the contamination risks of invasive procedures like
endomyocardial biopsy, outweigh the clinical benefit it may
derive from the knowledge of the histological and molecu-
lar cardiac substrate. However, although myocardial involve-
ment in HIV infection has been variously attributed to HIV
itself [1,2], opportunistic and viral infections [3], drug related
cardiac toxicity [4], nutritional deficiencies [5] and auto-
immune response to viral infection [6], no specific treatment
capable to substantially improve patients’ prognosis has been
recognized so far. As a consequence, HIV-related DCM is
usually managed with a supportive, anti-failing heart therapy
registering very often a grim outcome. In the following study
we report a chronic severe cardiac dilatation and dys-
function in a HIV-infected patient, caused by an auto-
reactive myocarditis, the recognition of which through* Correspondence: biocard@inmi.it
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steroid administration.
Case presentation
A 39-year-old HIV infected caucasian man was admitted
because of progressive heart failure beginning 9 months
earlier after an episode of upper respiratory tract infection.
His clinical history was marked by a serious compromise of
lymphocyte count (CD4+ lymphocytes 95/cmm) and high
blood viral load (1.3 × 106 copies/ml) at the time of HIV in-
fection recognition at the age of 29 years. He experienced
several infectious events including gastroenteritis, pneumo-
nia and toxoplasma encephalitis before the introduction of
anti- retroviral therapy seven years before. Since then he
was under antiretroviral treatment (ritonavir, darunavir and
emtricitabine/tenofovir) registering a recovery of lymphocyte
count (CD4+ up to 500/cmm) and an undetectable viral
load in the peripheral blood. The time course of heart failure
symptoms and laboratory/instrumental changes from anti-
retroviral therapy was about seven years. His heart failure
was characterized by progressive dyspnea, absence of fever
and chest pain but mild and constant increase of troponin T
(between 0.1 and 0.8 μg/L, normal values < 0.014). Thel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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min) with low QRS voltages while 2D-echocardiogram
showed normal valvular pattern but a progressive bi-
ventricular dilatation (right and left ventricular end diastolic
diameter was 36 and 68 mm respectively) and dysfunction
(RV and LV ejection fraction 35 and 25%) despite an opti-
mized dose of carvedilol (50 mg bid), digoxin (0.125 mg/
daily), enalapril (20 mg bid) and furosemide (up to 250 mg/
daily). Cardiac magnetic resonance showed a left ventricular
(LV) end-diastolic volume of 231.6 ml (Figure 1A), a LV
end-systolic volume of 184.2 ml (Figure 1B) and an ejection
fraction of 20% with remarkable edema (Figure 1C) and
delayed gadolinium enhancement of the lateral LV free wall
(Figure 1D), with minimal pericardial effusion.
Due to the presence of chronic, severe (NYHA class IV),
drug-resistant heart failure the patient underwent an in-
vasive cardiac study including coronary with LV angiog-
raphy and a LV endomyocardial biopsy with histology and
polymerase chain reaction for a large panel (HIV, Hepatitis
C virus, Human Herpes Virus 6, Human Herpes Virus 8,
Herpes Simples virus ½, Epstein Barr virus, Adenovirus,
Cytomegolovirus, Enterovirus, Influenza A/B, Parvovirus
B19) of cardiotropic viruses on 6 samples. Coronary net-
work was normal while at histology a severe active lympho-
cytic myocarditis was observed characterized by intense cell
necrosis (Figure 1E), marked expression of HLA-DR on
cardiomyocyte membrane (Figure 1F) and absence of de-
tectable viral genomes, including HCV. Serology for anti-
DNA, anti-cardiolipin and ANCA antibodies was negative
while it was positive for ANA (++/+++). Cardiac specificFigure 1 Cardiac magnetic resonance and left ventricular endomyocard
autoimmune myocarditis (lower panels) in HIV- infected patient. Long a
and dysfunctional left ventricle recovering (ejection fraction from 20 to 45%) a
T2 short-tau inversion recovery images (T2-STIR) in mid ventricular short axis s
of the left ventricular myocardium (panel C, arrows), and thickening of pericar
corresponding to late gadolinium enhancement (LGE) with the same distribu
(panel I and L) show complete regression of tissue edema and late enhancem
overexpression of HLA-DR on cardiomyocyte membrane (arrow in panel F, im
autoantibodies (panel F insert) resulted in healed myocarditis with disappeara
focal replacement fibrosis (panel N, Masson’s trichrome, 200x).autoantibodies were searched for by means of indirect im-
munofluorescence as previously described [7] and showed
a strong positivity in heart muscle while were negative in
skeletal muscle (Figure 1F insert). Supportive treatment
was, then, implemented by high dose steroid administration
(methylprednisolone 1 gr IV/daily for 3 days followed by
prednisolone 40 mg IV/bid for 1 week and then prednisone
1 mg/kg/daily orally) with rapid improvement of general
and cardiac conditions: in one week sinus tachycardia re-
duced from 125 to 78 bts/min, gallop rhythm was no more
appreciable and LVEF rose to 28%; after 4 months the pa-
tient reached a NYHA class I regaining a normal social life,
electrocardiogram registered a heart rate of 62 bts/min with
increase of QRS voltages and improvement of ventricular
repolarization while a new 2D-echocardiogram showed
remarkable reduction of LV volumes with nearly normal
LVEF. At control cardiac magnetic resonance, LV
end-diastolic volume reduced to 140.6 ml (from 231.6)
(Figure 1G), LV end-systolic volume declined to 77.7 ml
(from 184.2) (Figure 1H) and LVEF increased to 45%
(from 20%) while myocardial edema (Figure 1I) as well as
delayed enhancement (Figure 1L) and pericardial effusion
were no more appreciable.
Control histology showed a resolution of the inflam-
matory process (Figure 1M) with interstitial and replace-
ment fibrosis (Figure 1N).
Discussion and conclusions
The underlying myocardial damage in DCM has been
attributed to various causes and mechanisms [1-6], and itsial biopsy before (upper panels) and after recovery from
xis images (panel A = diastole, panel B = systole) show a severe dilated
fter 4 months of steroid treatment (panel G = diastole, panel H= systole).
how subepicardial edematous imbibition of the infero-lateral segment
dial layers with minimal amount of effusion (panel C, arrowheads)
tion (panel D, arrows). At 4-month follow up T2w-STIR e LGE images
ent. Severe lymphocytic myocarditis (panel E, H&E, 200x) with
munoperoxidase, 400x) and positivity of cardiac serum to antiheart
nce of inflammatory infiltrates (panel M, H&E, 200x) and interstitial and
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studies including coronary angiography and endomyocar-
dial biopsy. The latter procedure is sometimes not per-
formed because of the risk of unfavorable cardiac events
and of potential HIV exposure for healthcare workers. On
the other hand, use of non-invasive exams, including
cardiac magnetic resonance, is of limited informative value:
indeed, the possible observation of edema, hyperemia and
delayed gadolinium enhancement, suggesting the presence
of myocarditis, does not provide any causal information
useful to establish a specific treatment [8]. On the opposite,
histological and molecular study of endomyocardial biop-
sies can confirm the presence of myocarditis, define
through immunohistochemistry the pathologic type of
inflammatory infiltrate (lymphocytic, eosinophilic, granu-
lomatous, giant cell), identify by means of polymerase
chain reaction the offending infectious agent and then in-
dicate an appropriate therapeutic regimen. In particular
new promising antiviral agents as beta-interferon [9] are
emerging to contrast viral myocarditis, immunoglobulins
[10] and immunoadsorption [11] are a current option for
virus-positive and virus-negative respectively inflamma-
tory cardiomyopathy, while the recent prospective, ran-
domized TIMIC study [7] has given encouraging results
(cardiac improvement in 88% of treated patients) for the
immunosuppressive treatment of virus- negative myocar-
ditis. The present report suggests that auto-reactive
myocarditis, suggested by the positivity to anti-heart auto-
antibodies [12] is, perhaps, an underestimated cause of
DCM in HIV-infected patients and that its recognition,
through endomyocardial biopsy may lead to a prompt
steroid treatment with the recovery of cardiac dimensions
and function even in subjects in a terminal phase of heart
failure. The mechanism involved likely includes the reco-
very of immune-competence of lymphocytes by the ad-
ministration of antiretroviral agents and the lymphocytes’
reaction toward segregated myocyte antigens possibly
shared by viral structural components.
Finally HIV itself is supposed to modify lymphocyte gene
expression [13], leading eventually to the induction of an
autoimmune process. The auto-reactive nature of inflamma-
tory damage has been documented in our report by negative
polymerase chain reaction for a large panel of cardiotropic
viruses, the prominent HLA-DR expression in the sarco-
lemmal membrane of myocardiocytes and the extraordinary
response to steroid administration of a chronically failing
heart unresponsive to an optimized supportive therapy. This
observation encourages the invasive investigation of HIV-
associated DCM and the histological/molecular analysis of
endomyocardial tissue samples. In conclusion presence of
auto-reactive myocarditis should be considered in patients
with HIV-associated DCM. Its recognition by endomyocar-
dial biopsy followed by steroid administration may result in
a complete resolution of cardiac disease.Consent
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